Previous 10 | Next 10 |
SQZ Biotechnologies press release (NYSE:SQZ): FY GAAP EPS of -$2.49 beats by $0.26. Revenue of $27.1M (+29.1% Y/Y) beats by $5.22M. As of December 31, 2021, the company had cash and cash equivalents of $143.5 million and anticipates this will be sufficient to fund operating expenses and capit...
SQZ-PBMC-HPV-101 Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient as Demonstrated in December 2021 ESMO-IO Oral Presentation DSMB Recommended SQZ-PBMC-HPV-101 Advance Into Combination Stage with Checkpoint Inhib...
SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present new preclinical findings on the company’s enhanced antigen presenting cell (eAPC) platform at the American Assoc...
AlloVir manufactures T cells ex vivo, off-the-shelf, for curing viral infections in HSCT patients. Its technology has similarities and differences with a number of other companies, discussed here. ALVR presents an interesting approach to an unmet medical need. For further de...
Multiple Immune Cell Types – T cells, B cells, NK cells, and Monocytes – Demonstrate Engineering of MHC-I Antigen Presentation Paper on the Company’s Cell Squeeze® Platform’s Cell Engineering Capabilities Published in the February 15th Edition of Jou...
SQZ® Enhanced APCs (eAPCs) Build on Promising Initial SQZ® APC Monotherapy Clinical Data by Broadening the Addressable Patient Population and Incorporating Enhanced Immunological Functions to Increase Potency SQZ eAPCs are Created by Delivery of Multiple mRNAs Encodi...
SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that John Maraganore, Ph.D., founding CEO of Alnylam Pharmaceuticals, has joined the company as a strategic advisor. “John is an iconic b...
Patient’s Clinical, Radiographic and Histologic Results Support Potential Impact of SQZ Investigational Therapeutic Patient Demonstrated Symptomatic Improvement Radiographic Response Observed in Target Lesion Tumor Conversion from Desert to Inflame...
Interim SQZ-PBMC-HPV Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and that Therapy was Generally Well Tolerated Oral Presentation at ESMO Immuno-Oncology Congress on December 9 to Focus on Highest-Dose Monotherapy Cohort of SQZ™ APC Candidat...
Roche Accelerator Membership to Support Company’s Early Strategic Planning and Market Exploration in China SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its China Initia...
News, Short Squeeze, Breakout and More Instantly...
SQZ Biotechnologies Company Company Name:
SQZ Stock Symbol:
NYSE Market:
HOUSTON, June 20, 2023 (GLOBE NEWSWIRE) -- SEACOR Marine Holdings Inc. (NYSE: SMHI) (the “Company” or “SEACOR Marine”), a leading provider of marine and support transportation services to offshore energy facilities worldwide, today announced that it had entered into a ...
Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01B SQZ Biotechnologies Company (NYSE: SQZ) (the “Company” or “SQZ”), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the ...